The World Health Organization (WHO) classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors, and is based on the recognition of distinct diseases using a multidisciplinary approach. The updated classification refined the definitions of well recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities -categories for which the WHO working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an impact on practice guidelines. The authors address the criteria and significance of early or precursor lesions, and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities are reviewed. These new observations chart a course for future research in the field.
ABSTRACT
The World Health Organization (WHO) classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors, and is based on the recognition of distinct diseases using a multidisciplinary approach. The updated classification refined the definitions of well recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities -categories for which the WHO working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an impact on practice guidelines. The authors address the criteria and significance of early or precursor lesions, and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities are reviewed. These new observations chart a course for future research in the field.
Introduction
Classifications of diseases are the language of medicine -to categorize known entities in a way that facilitates understanding between workers in the field and to provide a framework for both clinical practice and the generation of new knowledge.
The World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues, published in 2001 and updated in 2008 represents a worldwide consensus on the diagnosis of these tumors, adopted for use by pathologists, clinicians and basic scientists 1 (Table 1) published by the International Lymphoma Study Group (ILSG) in 1994. 2 The validation of this proposal in a large series of tumors from different parts of the world 3 and the publication of the 3 rd edition of the WHO classification 1 ended a long history of controversies surrounding the classification of lymphomas. 4 The conceptual framework of the classification is likened to an evolving organism, and is permissive of change as advances in our knowledge occur. Thus, the WHO classification of 2008 refined the definitions of well recognized diseases, identified new entities and variants, and incorporated new emerging concepts in the understanding of lymphoid neoplasms. However, when published in 2008 some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities -categories for which the WHO working groups felt there was insufficient evidence to recognize as distinct diseases at this time.
The process of developing the 2008 WHO classification involved working groups of pathologists as well as a clinical advisory committee (CAC) of expert clinicians from around the world. A meeting of the CAC for lymphoid neoplasms together with the editors and lead authors of the WHO book was held at Airlie House, Warrenton, VA, March 8-9, 2007 . This report summarizes the process and rationale for the 2008 WHO classification of lymphoid neoplasms, emphasizing those diseases for which changes have had an impact on practice guidelines. In addition, since the 2008 For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From WHO publication, new findings and ideas have been generated. This review emphasizes and expands upon these emerging concepts. One such topic is the increased recognition of early or precursor lesions of lymphoid neoplasms. Additionally, while clinical features have been a part of disease definition since the REAL classification, it is increasingly recognized that some diseases are largely associated with particular age groups, such as children and the elderly. Finally, the 2008 WHO classification recognizes two provisional borderline categories of entities that have overlapping features with diffuse large B-cell lymphoma (DLBCL), as well as several other provisional entities.
New definitions and refinement of diagnostic criteria
The 2008 update of the WHO classification has adopted consensus guidelines for the definition of some well established diseases, including chronic lymphocytic leukemia (CLL), 5 lymphoplasmacytic lymphoma (LPL), Waldenström macroglobulinemia (WM), 6 and plasma cell neoplasms. 7 In addition, the WHO/EORTC consensus classification of cutaneous lymphomas was largely adopted. 8;9 The issue of grading of follicular lymphoma was revisited. The definitions of some categories of Tcell lymphomas including enteropathy associated T-cell lymphoma, anaplastic large cell lymphoma (ALCL) and subcutaneous panniculitis-like T-cell lymphoma have been refined.
Chronic lymphocytic leukemia
The increased sensitivity of immunophenotypic methodology has resulted in the incidental detection of clonal lymphoid cell proliferations with an aberrant immunophenotype in healthy individuals, even in the absence of clinical lymphocytosis.
These proliferations have been termed monoclonal B-cell lymphocytosis (MBL) (see below). 10;11 These observations led the International Workshop on CLL to propose new diagnostic criteria for CLL. 5 The requirement for a diagnosis of CLL was modified from a chronic absolute lymphocytosis above 5.0x10 9 /L to an absolute count of more than 5.0x10 9 /L monoclonal B-cells with a CLL immunophenotype in the peripheral blood (PB), in the absence of disease-related symptoms or cytopenias, or tissue involvement other than bone marrow. 5 A diagnosis of small lymphocytic lymphoma (SLL) is made when lymphadenopathy or splenomegaly due to infiltrating CLL cells is found, with fewer than 5x10 9 CLL-type cells in the blood. These criteria were accepted by the WHO CAC meeting in 2007 and were included in the definition of CLL in the 2008 WHO classification.
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From The selection of the cut-off was arbitrary, without clinical data supporting the number of 5x10 9 /L. Recent studies have confirmed that the number of clonal B-cells is clinically more relevant than the total lymphocyte count in predicting the outcome of the patients. The B-cell count is a continuous variable and the best thresholds vary around 10-11x10 9 /L in different studies. 12;13 An additional issue is the definition of SLL -that is, lymph node or other tissue involvement by an infiltrate characteristic of CLL but without the requisite number of PB monoclonal B-cells for a diagnosis of CLL. Similarly to PB, small clonal populations of CLL-type B cells may be detected in lymph nodes removed for the diagnosis of other conditions; minimal criteria for the diagnosis of SLL on tissue biopsy specimens may need to be developed if overdiagnosis is to be avoided. At a recent workshop of the European Association for Haematopathology and the Society of Hematopathology (Uppsala, September 2010), it was suggested that if the lymph node did not show enlargement and at least partial architectural effacement, a diagnosis of "lymph node involvement by monoclonal CLL-type B cells of unknown clinical significance", may be appropriate. Whether a minimal degree of lymph node involvement is sufficient to warrant a diagnosis of CLL rather than MBL remains to be determined. Since many patients with Rai Stage 0 CLL, even as currently defined, are not treated, the change in terminology relates more to how patients are "labeled", rather than indicating a change in patient management.
Lymphoplasmacytic lymphoma (LPL) and Waldenström's macroglobulinemia (WM)
Because many types of small B lymphoid neoplasms can demonstrate plasmacytic differentiation and specific immunophenotypic or genetic markers for LPL remain to be discovered, LPL is still defined in the 2008 WHO as a B-cell neoplasm composed of small lymphocytes, plasmacytoid lymphocytes and plasma cells, usually involving the bone marrow and sometimes the lymph nodes and spleen, which does not fulfill the criteria for any other B-cell neoplasm with plasmacytic differentiation. In addition, particularly since many marginal zone lymphomas with plasmacytic differentiation also lack defining biomarkers, the 2008 WHO openly acknowledges that sometimes only a diagnosis of small B-cell lymphoma with plasmacytic differentiation can be rendered and a differential diagnosis provided. Although documenting an IGH@/PAX5 (t(9;14)) translocation was previously thought to help diagnose a LPL, it is now recognized that it is rarely if ever found in LPL. Del6q occurs in about half of cases but is not a specific finding.
The definition of WM and its relationship to LPL have also been problematic.
The 2008 classification adopted the approach of the second International Workshop on WM, 6 which defined WM as the presence of an IgM monoclonal gammopathy of any For personal use only. on April 13, 2017. by guest www.bloodjournal.org From concentration associated with bone marrow involvement by LPL. Therefore LPL and WM are not synonymous, with WM now defined as a subset of LPL. The presence of even a large IgM paraprotein in the absence of a LPL is no longer considered WM, and LPL in the absence an IgM paraprotein is not WM.
Plasma cell neoplasms

Plasma Cell Myeloma (Multiple Myeloma)
Plasma cell neoplasms have proven challenging to classify in a biologically correct and clinically useful way. Since the immunoglobulin products of plasma cells are easily detected in the serum and urine, evidence of small clones of plasma cells may be detected by routine laboratory tests in patients who are healthy and may never develop organ damage secondary to the clonal proliferation. In addition, deposition of abnormal secreted immunoglobulin heavy or light chains or both (e.g. amyloidosis) in tissues may occur in the presence of a very small plasma cell clone, with organ damage that is due to the deposits, not related to the plasma cell burden. The definition of plasma cell myeloma (PCM) has rested on identifying clinical and laboratory features that predict when a sufficient burden of plasma cells has accumulated that the patient will benefit from treatment. Traditional classifications of PCM, including the 3rd edition of the WHO classification, recognized categories of monoclonal gammopathy with unknown significance (MGUS), smoldering myeloma, and indolent myeloma. These categories were intended to identify patients who did not require immediate treatment.
In the updated 2008 classification there were no recommendations for changing the definition of MGUS. However, since smoldering and indolent PCM are a continuum, neither can be reliably diagnosed prospectively, and both are asymptomatic, the term asymptomatic PCM is preferred. The presence of radiographically detected bone lesions, even if not symptomatic, would exclude a patient from this category, since these are an indication for treatment. Current guidelines of the International Myeloma Working Group therefore were adopted by the WHO 4th edition 7 ( Table 2) 
Follicular Lymphoma: Grading and variants
Follicular lymphoma (FL) has been traditionally graded into three categories since the days of the Rappaport classification. 15;16 The REAL and WHO 3 rd edition classifications recommended grading (grades 1-3) according to the number of centroblasts (0-5; 6-15, >15 per high power field, respectively). Grade 3 was further subdivided for the purposes of clinical research into 3A (centrocytes still present) and 3B (sheets of centroblasts). Many studies over decades have shown that the proportion of large cells (centroblasts) predicts clinical outcome, with a more aggressive course in For personal use only. on April 13, 2017. by guest www.bloodjournal.org From cases with increased centroblasts. However, the participants in the 2007 WHO Clinical Advisory Committee meeting agreed that there were several problems with this scheme. First, it is poorly reproducible among pathologists. Second, it is clear that there are no major biological or clinical differences between grades 1 and 2, and they are treated similarly. Finally, several publications since 2001 suggested that Grade 3B FL is biologically distinct from Grades 1-3A, with features suggesting a close relationship to DLBCL (more frequent lack of CD10 and Bcl2, expression of IRF4/MUM1, and rearrangement of BCL6 but not BCL2). [17] [18] [19] [20] These considerations led to the recommendation to group together FL grade 1-3A as "FL" and to create a new category for what has been called FL3B. While this idea was attractive to both pathologists and clinicians, there were several arguments against it. First, most studies that found a close relationship of FL3B to DLBCL actually included cases with diffuse areas (e.g., DLBCL); thus, these cases should not have been classified as FL3B according to the WHO 3 rd ed. Second, FL3B (with a purely follicular pattern) comprises only a small fraction of FL grade 3; thus, the clinical behavior of FL grade 3 in many clinical studies is based on the behavior of FL3A. Moreover, Hans et al 21 found no difference in outcome between FL3A and FL3B and another study, also based on cases with a purely follicular growth pattern, found a gene signature in FL3B that was closer to FL than to DLBCL of the GCB type. 22 Thus, the final decision was to combine FL grades 1 and 2 into one category (FL1-2 of 3), and make the distinction between FL3A and FL3B mandatory, rather than optional. This issue will need to be revisited when more data are available.
Some studies have suggested that the proliferative index recognized with Ki-67 labeling may represent a complementary aid or even an alternative to the morphological grading of FL. 23;24 However, determination of proliferation index is also subjective and can be influenced by staining technique, so that this information also needs to be used judiciously.
The genetic hallmark of FL is the t(14;18) translocation and oncogenic BCL2 activation. However, as noted some grade 3 FL, particularly grade 3B do not carry this translocation. 25 Similarly, the 4 th Edition of the WHO classification recognizes some distinctive clinical and genetic subtypes of FL, such as primary duodenal FL and the pediatric type of FL. Primary duodenal FL carries the t(14;18), but usually remains localized to the intestinal mucosa. In contrast, pediatric FL lacks the t(14:18), and usually presents with localized disease. The concept that lymphomas in children often differ from lymphomas in adults is a recurrent theme in the 2008 classification, as will be discussed below.
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Several studies since the publication of the updated classification have expanded upon these observations, emphasizing that not all B-cell lymphomas with a follicular growth pattern, or derived from follicular B-cells are part of the same disease process. In particular, several variants of FL lacking the t(14;18) appear to show some distinctive features. Thus, predominantly diffuse FL with frequent deletions of 1p36 have been recognized in patients presenting with localized bulky disease, mainly in the inguinal region. 26 Some cases of t(14;18)-negative FL with conventional morphology resemble activated late-stage germinal center B-cells by gene expression profiling (GEP), 27 while some show intrafollicular plasma cell differentiation. 28 The current classification retains these t(14;18) negative cases within the broad group of FL, an issue that will have to be addressed in the future as more clinical and genetic data are obtained.
Newly defined entities and categories
The 2008 classification has delineated some new lymphoma entities. Some had been described previously, but had been considered morphological or phenotypic variants of other entities; new evidence supports their distinction as independent diseases.
Diffuse large B-cell lymphomas
The clinical and biological heterogeneity of DLBCL has been appreciated for some time. The WHO working group delineated some newly defined entities based on distinctive clinical, pathological or biological features. This expanded list of diseases has stirred some controversy regarding the practicality of handling the diversity of these tumors. Some of the new lesions are uncommon or affect limited subsets of patients.
However, their recognition serves two goals: delineating a more homogeneous group of DLBCL for clinical trials, while facilitating the study of rare variants, which may require specialized approaches. The vast majority of DLBCL do not have specific clinical or pathologic features and, therefore, are included in the group of DLBCL, not otherwise specified (NOS). GEP has provided new insights, leading to the identification of two principal molecular subtypes, the germinal center (GCB) and activated B-cell (ABC) forms of DLBCL. These subsets are associated with specific genetic alterations, different molecular signaling pathways, and different clinical outcomes. 29 A variety of immunohistochemical algorithms have been proposed to delineate these subsets in the routine clinical laboratory. 30 The difficulties in reproducibly distinguishing these subsets in the absence of GEP persuaded the WHO committee not to require their distinction in daily clinical practice. However, new therapeutic strategies are being designed to For personal use only. on April 13, 2017. by guest www.bloodjournal.org From differentially treat GCB and ABC DLBCL. 31 These advances will spur the development of novel tools that can be used in the routine clinical laboratory. 32 The new classification emphasizes the importance of the location and other clinical aspects in the diagnosis of certain entities (see below). Similar to the well recognized primary mediastinal large B-cell lymphoma (PMBCL), other DLBCL originating in specific topographic locations are considered specific entities. These tumors include DLBCL of the central nervous system (CNS) and primary cutaneous DLBCL, leg type. Primary CNS DLBCL has a particular gene expression and genomic profile that differs from nodal DLBCL and the patients are managed with different protocols. [33] [34] [35] The distinction of primary cutaneous DLBCL, leg type, as a specific entity was based on its aggressive clinical behavior and phenotype that differ from the more indolent primary cutaneous follicle center lymphomas, even if composed mostly of large lymphoid cells. Notably, DLBCL of leg type resembles systemic DLBCL of the ABC subtype by GEP. 36;37 We foresee that in the near future the taxonomy of DLBCL will rely more on integrated molecular and genetic parameters rather than on particular clinical features, but it is still possible that the clinical presentation may still determine the management strategy.
The recognition of T-cell/histiocytic rich large B-cell lymphoma (THRLBCL) as a distinct category of DLBCL highlights the importance of the microenvironment in the biology of some diseases. GEP studies have identified a subgroup of DLBCL with a high host immune response signature and a bad prognosis that includes most of these cases. 38 The morphological and phenotypic similarities between some THRLBCL and progressed forms of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) have suggested a possible relationship between these neoplasms. Further studies may clarify whether de novo THRLBCL can be distinguished from such secondary cases.
The new classification recognizes several DLBCL entities characterized by EBV infection of the tumor cells. In addition to lymphomatoid granulomatosis, the WHO now includes EBV positive DLBCL of the elderly initially described in Asia [39] [40] [41] [42] and DLBCL associated with chronic inflammation, most often chronic pyothorax. [43] [44] [45] [46] In these lesions EBV infected cells frequently express a latency type 3 with positivity for the viral proteins LMP-1 and EBNA-2 suggesting that the lymphoid proliferation may be related primarily to a decrease in the host immunosurveillance. These cases typically have a rich inflammatory background, but are excluded from THRLBCL. EBV positive DLBCL of the elderly is still considered a provisional entity that requires a more precise definition and distinction from other EBV related disorders including reactive lesions, EBV positive classical Hodgkin's lymphoma and the recently described mucocutaneous ulcer. [47] [48] [49] The term EBV positive DLBCL of the elderly emphasizes the tendency of these lesions to present at advanced age, although there is no sharp age limit and similar lesions may be found in younger individuals. To date reports of these tumors in 
Enteropathy associated T-cell lymphoma
The 
Early lesions in lymphoid neoplasms
The idea of malignant transformation of cells through a multistep process of accumulating genetic and molecular events is well accepted and recognized in solid tumors. These concepts have been difficult to apply in the lymphoid system where the cells naturally circulate and colonize different tissues. 62 Molecular studies had detected oncogenic chromosomal translocations in the blood or bone marrow cells of otherwise healthy individuals. More recently histological and immunophenotypic correlates of these molecular events have been identified. The new WHO classification addresses the increasing recognition of clonal expansions of lymphoid cells that appear to correspond to early steps in lymphomagensis. In some cases it is not clear whether these lesions will ever progress to clinically significant disease, or whether they simply correspond to relatively stable "benign lymphoid" clonal proliferations. The identification of these lesions opens new questions as to how to manage these patients.
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From The recognition of monoclonal B-cell lymphocytosis (MBL) as a potential precursor of CLL and, less frequently, other leukemic lymphoid neoplasms, has stirred a number of clinical and biological studies that have altered the traditional diagnosis of CLL. MBL is frequently found in first-degree family members of CLL patients and in 5% of tested subjects over the age of 60 years old but the incidence increased to 14% in subjects with lymphocytosis (>4000/ mm 3 ). 10;63;64 Population based studies and the use of highly sensitive detection methods have identified clonal B-cells in 12% of the population and more than 20% of individuals above 65 years. 65 Epidemiological studies have found evidence of the CLL clone in the blood many years prior to diagnosis, supporting the idea of a long silent phase. 66 The rate of progression of MBL to overt CLL is around 1-2% per year. 64 However, it seems that the majority of individuals with MBL will not develop clinically relevant lymphoid neoplasia during their lifespan. MBL detected by random screening shows some biological differences in the immunoglobulin gene repertoire as compared to CLL or other MBL. [65] [66] [67] Moreover, patients with MBL may manifest oligoclonal or polyclonal expansions of similar cells. Thus, with aging multiple MBL clones may exist but only some of them will be selected to progress to clinically relevant disease. The driving forces in the origin, expansion and selection of these clones are not known. Early possibly neoplastic or pre-neoplastic proliferations corresponding to the immunophenotypic and molecular phenotypes of follicular or mantle cell lymphoma, have been observed in tissues. These have been designated as "in situ" FL or "in situ" MCL, referring to the fact that the clonal population is restricted in its distribution to its normal anatomic location, the germinal center or mantle zone, respectively (Table   3 ) (Fig 2) . [69] [70] [71] [72] [73] [74] [75] [76] These lesions should be distinguished from partial involvement of the lymph node by overt lymphomas. Cases of "in situ" FL, or intrafollicular neoplasia, as alternatively termed in the WHO classification, represent expansions of CD10 and BCL2 positive lymphoid cells carrying the t(14;18) translocation found in germinal centers of an otherwise reactive lymph node. The finding is usually incidental, the involved follicles often scattered, and generally not completely replaced by BCL2positive cells. In some patients disseminated FL is discovered upon staging, but probably more than 50% of the patients do not have evidence of FL beyond the initial For personal use only. on April 13, 2017. by guest www.bloodjournal.org From node and with existing follow-up. 70;72 This situation may represent tissue infiltration of circulating antigen-experienced, clonal expansions of B-cells carrying the t (14;18) translocation commonly detected in healthy individuals, termed FL-like B-cells. 77 These circulating t(14;18)-positive clones, which are more prevalent among individuals with pesticide exposure, appear to lack additional oncogenic events to develop into an overt lymphoma. It is interesting that some individuals may carry several different clones with the t (14, 18) , although usually one of them largely predominates over the others, suggesting that these clones may arise in a context that facilitates the translocation and subsequent expansion. 78 Interestingly, some HCV patients have clones carrying the t(14;18) that may disappear following anti-viral therapy. 79 Early involvement of lymph nodes by cells carrying the t(11;14) translocation and overexpressing cyclin D1 have been reported in several individual cases. 69;71;73;74;76 The cyclin D1 expressing cells are predominantly found in the inner area of the mantle zone of the follicles but usually the rest of the mantle and the follicle have a reactive appearance. The finding is usually incidental in an otherwise reactive lymph node.
Some of these patients have circulating t(11;14)-positive cells, but have not developed a clinically significant neoplasm after several years of follow-up, even without treatment. 71;73 However, some cases may progress to overt MCL. 76 Similar to the t(14;18) translocation, persisting circulating clones carrying the t(11;14) translocation may be detected in healthy individuals, again without evidence of progression. 80 On the other hand, some patients with clinically detected MCL, usually presenting with leukemic but non-nodal disease, also can have very stable disease for many years even without chemotherapy. 81 These cases lack chromosomal aberrations other than the t(11;14) and show differential expression of SOX11 and other genes of the high mobility group of transcription factors, in comparison with conventional MCL. 81;82 These observations challenge our current view of the pathogenesis and evolution of MCL and may warrant altered therapeutic strategies based on particular biological characteristics. For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Besides location, age has become a significant factor in the recognition of some new lymphoma entities. We previously discussed EBV positive DLBCL of the elderly.
Clinical features in disease definition
At the other end of the spectrum, some pediatric lymphomas have clinical and pathological features that differ from the corresponding counterparts in adults.
Follicular lymphomas in children tend to present with localized disease in nodal and extranodal sites and are frequently composed of large cells. In spite of high grade (Grade 3) cytology they have a good prognosis with very few relapses. The t (14;18) translocation or BCL6 rearrangements are uncommon although BCL2 protein expression may be found in up to 50% of the tumors. 83 Recurrent breaks in the IG gene are seen in a number of cases but the corresponding partners have not been identified. [83] [84] [85] Some patients have had long survival with only local treatment, and the most appropriate management of these patients is yet to be defined. It may emerge in a background of chronic active EBV-infection, and progress from a polyclonal, to oligoclonal, to monoclonal EBV driven proliferation. 94 These lesions may occur less often in young adults.
Gray zones between Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
In the past 20 years there has been a greater appreciation of morphologic and immunophenotypic overlap between some large B-cell lymphomas and classical Hodgkin's lymphoma (CHL) -particularly nodular sclerosis(NS) CHL of the mediastinum and PMBL. 95 GEP studies further revealed that PMBCL and CHL share a common gene expression signature, supporting a close biological relationship. 96;97 Several reports had recognized the simultaneous or sequential diagnosis of otherwise conventional PMBL and CHL in the same patient. 98 More recently tumors with transitional or intermediate morphological and phenotypic features between these two entities were described (Fig 3) . 95;99 These observations suggested that a true biological gray zone between these two entities could exist, a finding supported by profiling at the epigenetic level. 100 this concept it appears that these tumors occur predominantly in young men and have more aggressive behavior than either PMBL or NSCHL. The optimal therapeutic management of these lymphomas has not been determined. Recent biological studies have begun to yield insights into the mechanisms modulating the plasticity of the neoplastic B-cells and tumor microenvironment in CHL and DLBCL, 100;101 and may provide data relevant to improved therapies. 102
Gray zones between Burkitt and Diffuse Large B-cell Lymphoma
The diagnostic criteria for Burkitt and DLBCL have been relatively well defined for many years. However, pathologists have always encountered cases with intermediate features between these categories that have been difficult to classify. The different names that these tumors have received over the years such as Burkitt-like lymphoma, small non-cleaved cell lymphoma, non-Burkitt type, and high-grade B-cell lymphoma among others, reflect their imprecise definition and limits in our conceptual understanding. Not surprisingly, these borderline cases have been among the least For personal use only. on April 13, 2017. by guest www.bloodjournal.org From reproducible diagnoses, even among expert pathologists. 3 Two recent GEP studies of Burkitt's lymphomas (BL) have provided evidence that the difficulties among pathologists to recognize the border between BL and DLBCL reflect a true biological gray zone. One study found the molecular signature of BL (mBL) in a group of cases diagnosed as DLBCL or high grade B-cell lymphomas. 103 In spite of the mBL signature these cases differed clinically and genetically from classical BL. They were identified in older patients, had a equal male:female ratio, and very complex karyotypes including simultaneous t(8;14) and t(14;18) translocations ("double-hit" tumors). The clinical behavior was very aggressive. 104 Similarly, a second GEP study of BL found a subset 
Open questions and future challenges
The 2008 WHO classification of lymphoid neoplasms has been a major consensus effort in updating new knowledge, concepts and criteria in the taxonomy of these neoplasms. However, many questions still remain.
Similar to DLBCL, peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS) probably include multiple entities, but we lack criteria and biomarkers to recognize them. The recent identification of T-follicular helper cells (T FH ) has allowed us to relate angioimmunoblastic lymphoma (AILT), one of the major types of PTCL, to this type of germinal center T-cell. 108;109 A follicular variant of T-cell lymphoma has been recognized that also seems to originate from these cells, with some cases carrying the For personal use only. on April 13, 2017. by guest www.bloodjournal.org From t(5;9) translocation fusing ITK to SYK. 110;111 However, it is not clear if all PTCL expressing T FH markers correspond to the same entity. 112 In spite of the recognition of some specific subtypes, most PTCL still remain under a broad category of "not otherwise specified". In contrast to what occurred among DLBCL, GEP has not dramatically changed the PTCL, NOS scenario by allowing specific subtype identification. Although GEP identified a cytotoxic subgroup with more aggressive behavior, 58 a similar conclusion had been suggested previously in a series analyzed by immunohistochemistry. 113 Our lack of success is likely secondary to the relative rarity of PTCL, the heterogeneity of the cellular infiltrates, comprising neoplastic and reactive cells, and our limited knowledge of the normal cellular counterparts. Nevertheless, GEP studies have provided some information concerning novel therapeutic targets 111;114 that are potentially important in light of the lack of sensitivity to conventional chemotherapies. 115 The major premise of the REAL and WHO classifications has been that lymphomas were distinct and non-overlapping disease entities, which could be defined the classic pathological and immunophenotypic approach to the study of lymphomas has been a robust and successful tool of disease discovery. 4 However, genetic and genomic approaches have proved instrumental in defining the molecular identities of diseases, providing new prognostic models, and identifying molecular pathogenetic pathways that may be targets of new therapeutic drugs. Wide genome screening of genetic alterations is starting to provide insights into the genetic susceptibility of some entities and the discovery of a broader spectrum of oncogenic mutations relevant in the pathogenesis of these tumors than previously known. [122] [123] [124] [125] The next generation of sequencing technologies with the possibility of elucidating the whole genome sequence of large number of tumors at an affordable cost is the next step starting to produce early results. 101;126;127 The new technologies promise new insights into basic biology, allowing us to refine our clinical and pathological perspective. Classifications, as a reference framework between research and clinical practice, will continue to evolve, keeping pace with new discoveries and knowledge. For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Table 3 : Differential features between "in situ" and partial involvement by follicular and mantle cell lymphoma For personal use only. on April 13, 2017. by guest www.bloodjournal.org From
